Literature DB >> 2185297

Assessment of hepatic function. Comparison of caffeine clearance in serum and saliva during the day and at night.

A Wahlländer1, S Mohr, G Paumgartner.   

Abstract

Hepatic microsomal function was assessed by a caffeine clearance test at night and during the day using saliva and serum samples obtained simultaneously. In 26 patients with cirrhosis, 21 patients with noncirrhotic liver disease and 15 control subjects caffeine elimination correlated well during the day and at night (r = 0.915 for serum and 0.917 for saliva). The correlation coefficients for caffeine clearance in saliva and serum were 0.940 during the day and 0.963 overnight. In the cirrhotic patients, clearance differed significantly from noncirrhotic liver disease and controls in saliva samples overnight: 0.51 +/- 0.45 ml/min per kg versus 0.91 +/- 0.44 and 1.41 +/- 0.56, respectively. Comparable results were obtained for serum clearance overnight and clearances during the day. Serum and saliva clearances at night correlated well with the aminopyrine breath test (rs = 0.884 and 0.907, respectively). Overnight caffeine clearance in saliva might be a simple useful method for assessing progression and prognosis of liver disease.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2185297     DOI: 10.1016/0168-8278(90)90041-o

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  9 in total

Review 1.  Alternative Sampling Strategies for Cytochrome P450 Phenotyping.

Authors:  Pieter M M De Kesel; Willy E Lambert; Christophe P Stove
Journal:  Clin Pharmacokinet       Date:  2016-02       Impact factor: 6.447

2.  The role of salivary caffeine clearance in the diagnosis of chronic liver disease.

Authors:  Anurag Tripathi; Brijesh Tiwari; Ranjit Patil; Vikram Khanna; Vandana Singh
Journal:  J Oral Biol Craniofac Res       Date:  2015-01-23

3.  Caffeine clearance by enzyme multiplied immunoassay technique: a simple, inexpensive, and useful indicator of liver function.

Authors:  J E McDonagh; V V Nathan; I C Bonavia; G R Moyle; A R Tanner
Journal:  Gut       Date:  1991-06       Impact factor: 23.059

4.  Functional elements associated with hepatic regeneration in living donors after right hepatic lobectomy.

Authors:  Gregory T Everson; John C Hoefs; Claus U Niemann; Kim M Olthoff; Robert Dupuis; Shannon Lauriski; Andrea Herman; Norah Milne; Brenda W Gillespie; Nathan P Goodrich; James E Everhart
Journal:  Liver Transpl       Date:  2013-03       Impact factor: 5.799

5.  Influence of age, frailty and liver function on the pharmacokinetics of brofaromine.

Authors:  J Zeeh; L Fuchs; W Bergmann; K H Antonin; F Degel; P Bieck; D Platt
Journal:  Eur J Clin Pharmacol       Date:  1996       Impact factor: 2.953

6.  Parkinson's disease and CYP1A2 activity.

Authors:  J T Forsyth; R A Grünewald; A Rostami-Hodjegan; M S Lennard; H J Sagar; G T Tucker
Journal:  Br J Clin Pharmacol       Date:  2000-10       Impact factor: 4.335

7.  Pharmacokinetics of naftopidil, a novel anti-hypertensive drug, in patients with hepatic dysfunction.

Authors:  M J Farthing; E M Alstead; S M Abrams; G Haug; A Johnston; R Hermann; G Niebch; P Ruus; K H Molz; P Turner
Journal:  Postgrad Med J       Date:  1994-05       Impact factor: 2.401

8.  Prognostic value of generation of growth hormone-stimulated insulin-like growth factor-I (IGF-I) and its binding protein-3 in patients with compensated and decompensated liver cirrhosis.

Authors:  N Assy; Z Hochberg; R Enat; Y Baruch
Journal:  Dig Dis Sci       Date:  1998-06       Impact factor: 3.199

Review 9.  Pharmacokinetics of Caffeine: A Systematic Analysis of Reported Data for Application in Metabolic Phenotyping and Liver Function Testing.

Authors:  Jan Grzegorzewski; Florian Bartsch; Adrian Köller; Matthias König
Journal:  Front Pharmacol       Date:  2022-02-25       Impact factor: 5.810

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.